BPMC News and Press, Blueprint Medicines Corporation From 03/02/23

The following slide deck was published by Blueprint Medicines Corporation in conjunction with this event. For further details see: Blueprint Medicines (BPMC) Presents At AAAAI Conference

Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting PR Newswire -- AYVAKIT achieved a statistically significant and clinically meaningful improvement in ...

Blueprint Medicines ( NASDAQ: BPMC ) announced Thursday that Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) has decided to end its collaboration agreement for Gavreto, an FDA-authorized therapy for certain cancer types caused by a genetic mutation called RET. Accordingly, Blueprint ( ...

Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche PR Newswire CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and developme...

Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Conference Call February 16, 2023, 08:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer C...

Blueprint Medicines press release ( NASDAQ: BPMC ): Q4 GAAP EPS of -$2.65 beats by $0.02 . Revenue of $38.78M (-63.8% Y/Y) beats by $5.26M . Revenues were $38.8 million for the fourth quarter of 2022, including $30.1 million of net product revenues from sales of AYVAKI...

Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results PR Newswire -- Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues -- -- Continued progress towa...

Blueprint Medicines ( NASDAQ: BPMC ) shed ~2% pre-market Friday after announcing that the FDA placed a partial clinical hold on its Phase 1/2 VELA trial for cancer candidate BLU-222. According to verbal communication from the agency, the decision followed transient, reversible vis...

Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222 PR Newswire CAMBRIDGE, Mass. , Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) ve...

Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023 PR Newswire CAMBRIDGE, Mass. , Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live co...